

Second Opinion: Investigators Provide Perspectives on the Current and Future Management of Small Cell Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following efficacy outcomes best represents results from the Phase III IMforte trial evaluating first-line maintenance therapy with lurbinectedin/atezolizumab after induction therapy with atezolizumab/carboplatin/etoposide for patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC)?
  - a. A numerical but nonsignificant improvement in progression-free survival (PFS) and overall survival (OS)
  - b. A significant improvement in PFS and a numerical but nonsignificant improvement in OS
  - c. A statistically significant improvement in both PFS and OS
2. Which of the following statements best describes the CNS activity of tarlatamab?
  - a. Tarlatamab is most efficacious in patients without baseline brain metastases
  - b. Tarlatamab demonstrates durable responses regardless of the presence of brain metastases at baseline
  - c. Tarlatamab crosses the blood-brain barrier and may require monitoring of intracranial pressure
3. Which of the following is a rare but serious adverse event associated with ifinatamab deruxtecan?
  - a. QT interval prolongation
  - b. Venous thromboembolism
  - c. Myocarditis
  - d. Interstitial lung disease
4. Which of the following descriptions best characterizes the study design of the Phase III EVOKE-SCLC-04 trial?
  - a. A Phase II study evaluating sacituzumab govitecan with lurbinectedin for previously treated ES-SCLC
  - b. A Phase III study evaluating sacituzumab govitecan versus chemotherapy for previously treated ES-SCLC
  - c. A Phase III study evaluating the combination of sacituzumab govitecan and atezolizumab versus atezolizumab/platinum/etoposide for previously untreated ES-SCLC
5. In the Phase III ADRIATIC study, the addition of consolidation durvalumab after the completion of chemoradiation therapy for patients with limited-stage SCLC yielded an improvement in OS of approximately ...
  - a. 2.5 months
  - b. 8.5 months
  - c. 10.5 months
  - d. 22.5 months